Craft

TCM Biotech

Stock Price

NT$60.2

2024-10-29

Market Capitalization

NT$3.6 B

2024-10-29

Revenue

NT$685.5 M

FY, 2025

TCM Biotech Summary

Company Summary

Overview
TCM Biotech (泰宗生物科技股份有限公司, also known as Taizong Biotechnology) is a biotech company that specializes in the research and development of drugs. It offers medical devices, osteoarthritis treatment products, anti-diabetic preparations, anti-adhesion systems, etc.
Type
Public
Status
Active
Founded
1998
Website
http://www.tcmbio.com
Cybersecurity rating
Sectors

Table of Contents

TCM Biotech Financials

Summary Financials

Revenue (Q1, 2026)
NT$172.9M
Gross profit (Q1, 2026)
NT$83.3M
Net income (Q1, 2026)
(NT$26.3M)
Cash (Q1, 2026)
NT$292.6M
EBIT (Q1, 2026)
(NT$27.1M)
Enterprise value
$3.3B

Footer menu